Hepatocyte high-mobility group box 1 protects against steatosis and cellular stress during high fat diet feeding

Minjie Lin  
University of Pittsburgh  https://orcid.org/0000-0002-3780-2600

Jungke Long  
University of Pittsburgh

Wenbo Li  
University of Pittsburgh

Chenxuan Yang  
University of Pittsburgh

Patricia Loughran  
University of Pittsburgh

Robert O'Doherty  
University of Pittsburgh

Timothy R. Billiar  
University of Pittsburgh

Meihong Deng  
University of Pittsburgh

Melanie J. Scott (✉ scottm@upmc.edu)  
University of Pittsburgh  https://orcid.org/0000-0001-6864-5970

Research article

Keywords: NAFLD, hepatic steatosis, liver injury, ER stress, β-oxidation

Posted Date: October 19th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-30696/v3

License: ☇️ .unpack This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

Version of Record: A version of this preprint was published on November 25th, 2020. See the published version at https://doi.org/10.1186/s10020-020-00227-6.
Abstract

Background: Circulating high-mobility group box 1 (HMGB1) plays important roles in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Intracellular HMGB1 is critical for the biology of hepatocytes. However, the intracellular role of HMGB1 in hepatocellular steatosis is unknown. Therefore, we aimed to investigate the role of hepatocyte-specific HMGB1 (HC-HMGB1) in development of hepatic steatosis.

Methods: Wild type (WT) C57BL/6 and HC-HMGB1−/− mice were fed high-fat diet (HFD) or low-fat diet (LFD) for up to 16 weeks.

Results: As expected, HMGB1 translocated from nuclear into cytoplasm and released into circulation after HFD treatment. HC-HMGB1 deficiency significantly reduced circulating HMGB1, suggesting that hepatocyte is a major source of circulating HMGB1 during NAFLD. Unexpectedly, HC-HMGB1 deficiency promoted rapid weight gain with enhanced hepatic fat deposition compared with WT at as early as 4 weeks after HFD treatment. Furthermore, there was no difference between WT and HC-HMGB1−/− mice in glucose tolerance, energy expenditure, liver damage or systemic inflammation. Interestingly, hepatic gene expression related to free fatty acid (FFA) β-oxidation was significantly down-regulated in HC-HMGB1−/− mice compared with WT, and endoplasmic reticulum (ER) stress markers were significantly higher in livers of HC-HMGB1−/− mice. In vitro experiments using primary mouse hepatocytes showed absence of HMGB1 increased FFA-induced intracellular lipid accumulation, accompanied by increased ER-stress, significant downregulation of FFA β-oxidation, and reduced oxidative phosphorylation.

Conclusions: Our findings suggest that hepatocyte HMGB1 protects against dysregulated lipid metabolism via maintenance of β-oxidation and prevention of ER stress. This represents a novel mechanism for HMGB1-regulation of hepatocellular steatosis, and suggests that stabilizing HMGB1 in hepatocytes may be effective strategies for prevention and treatment of NAFLD.

Background

The global epidemic of nonalcoholic fatty liver disease (NAFLD) poses a drastic threat to public health systems because of its increasing incidence around the world, especially in Western countries. In the United States, NAFLD is one of the most common chronic liver conditions, affecting an estimated 80 to 100 million individuals(1). The condition covers a wide range of liver changes, from simple steatosis and non-alcoholic steatohepatitis (NASH) to liver cirrhosis and hepatocellular carcinoma (2). The hallmark of NAFLD is abnormal lipid accumulation in the liver. Patients with NAFLD are at increased risk of liver-related as well as cardiovascular mortality, and NAFLD is closely linked to metabolic comorbidities, including obesity, insulin resistance, type 2 diabetes and metabolic syndrome (3). Although much attention has focused on NAFLD in recent decades, its pathogenesis remains largely obscure.

High-mobility group box 1 (HMGB1) is a highly conserved, ubiquitous nuclear protein constitutively expressed in nearly all cell types (4). Absence of HMGB1 in global knockout mice is lethal within a few
days of birth, with newborn knockout mice succumbing to hypoglycemia (5), although HMGB1 can be inducibly knocked out globally in adult mice (6), suggesting a specific role for HMGB1 in development and early metabolism. HMGB1 has separate intracellular and extracellular functions (7). Under physiologic conditions, as a structural component in the chromatin complex it is involved in maintaining DNA structure in the nucleus and influences multiple processes such as DNA binding, replication, repair and bending, and gene transcription and stability (8-10). In response to cellular stress HMGB1 is mobilized from the nucleus into the cytoplasm, where it can influence intracellular processes such as autophagy. HMGB1 can also be actively and passively released from cells where it can act as a pro-inflammatory damage-associated molecular pattern (DAMP)(11).

Recently, HMGB1 has been identified as a potent inflammatory mediator in several liver diseases (2), and mounting evidence indicates an important role of extracellular HMGB1 in the development of NAFLD (12). HMGB1 translocates from nucleus to cytoplasm in NAFLD (13), and circulating HMGB1 accelerates HFD-induced liver damage and inflammation during early stages of NAFLD (13). In addition, circulating HMGB1 level also correlates with the severity of inflammation and hepatic fibrosis associated with NAFLD (14, 15), and inhibition of HMGB1 release from hepatocytes, or treatment with neutralizing antibodies to HMGB1, attenuates liver damage during NAFLD (16). However, intracellular functions of HMGB1 in the pathogenesis of NAFLD are unexplored. We and others have observed that total HMGB1 in hepatocytes decreases in response to fatty acid stimulation (17). However, whether loss of intracellular HMGB1 in hepatocytes also plays a role in the pathogenesis of NAFLD is unclear.

We explored roles of hepatocyte-specific HMGB1 (HC-HMGB1) using cell-type specific knockout mice, generated using cre-lox technology (18), to mimic in vivo the loss of intracellular HMGB1. We found that HC-HMGB1−/− mice had early, rapid weight gain with significantly increased lipid accumulation compared with WT controls. Liver and hepatocytes from HC-HMGB1−/− mice also had increased evidence of endoplasmic reticulum (ER) stress, which was associated with decreased hepatic β-oxidation. Our findings uncover a novel role for intracellular HMGB1 in hepatocytes in the regulation of lipid metabolism.

Methods

Animal use and treatment. All animal protocols were approved by the animal care and use committee of the University of Pittsburgh, and experiments were performed in strict adherence to the National Institutes of Health Guidelines for the Use of Laboratory Animals. Male wild-type (WT) C57BL/6 mice were purchased from The Jackson Laboratory (no.000664). HC-HMGB1−/− mice were bred at our facility as described previously (18). Mice were housed four per cage. Starting at 10 weeks of age, mice of similar starting weights were randomized to either get high-fat diet (HFD) (45%kcal%fat; D12451, Research Diets, New Brunswick, NJ, USA) or low-fat diet (LFD) (10%kcal%fat; D12450K, Research Diets, New Brunswick, NJ, USA) for up to 16 weeks. See Supplemental Table 1 for Composition of rodent special diets. Mouse weight and food intake were measured weekly. Housing conditions and access to food and water were the same for all mice. Mice were euthanized under ether anesthesia and blood was obtained by cardiac
puncture. Liver tissue was removed after perfusion with cold phosphate-buffered saline, and then either immediately fixed in 2% paraformaldehyde or snap-frozen in liquid nitrogen.

**Body fat composition, energy expenditure and glucose tolerance test (GTT).** Whole-body fat was measured in conscious mice using magnetic resonance spectroscopy (EchoMRI-100; Echomedical Systems, Houston, TX) (19). To evaluate energy expenditure, O_2 consumption was monitored by The Comprehensive Lab Animal Monitoring System (CLAMS) (Columbus Instruments, Columbus, OH). Blood glucose was measured using a TRUEtrack blood glucose meter (TRIVIDIA, Fort Lauderdale, FL, USA) in blood collected from the tails of mice. The TRUEtrack® System exceeds the minimum International Organization for Standardization (ISO) standards for accuracy with 96.5% of results within the ISO defined limits. Mice were fasted for 6h before the test with free access to water. Blood glucose was then measured just before the intraperitoneal glucose injection (1 g/kg body wt in saline) and subsequently at 15, 30, 60, 90, and 120 min post-administration.

**Biochemical analyses.** Serum alanine amino-transferase (ALT) levels were measured using the DRI-CHEM 4000 Chemistry Analyzer System (Heska, Des Moines, IA). Serum interleukin (IL)-6 levels in mice were detected by an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, no.M6000B; sensitivity: 1.8 pg/mL). HMGB1 was quantified using by ELISA (TECAN, no.ST51011; sensitivity: 2.5 ng/mL).

**Histology.** Specimens were fixed in 10% neutral buffered formalin, paraffin embedded, and sectioned. Hepatic lipid accumulation was evaluated using hematoxylin and eosin (H&E)-stained histological sections. Steatosis was graded as: 0, 0% to 5% of the hepatocytes in the section are steatotic; 1, greater than 5% to 33% of hepatocytes are steatotic; 2, greater than 33% to 66%; and 3, greater than 66% (20). All histology was assessed by an investigator blinded to treatment group.

**Immunofluorescent staining.** Liver tissue was removed after perfusion with cold phosphate-buffered saline and 2% paraformaldehyde. Tissue was then placed in 2% paraformaldehyde for an additional 2h of further fixation, followed by 3 changes in 30% sucrose in distilled water over 24h. Tissue sections of 5 μm were incubated with 5% normal goat serum for 45 min. Samples were incubated with 2 μg/ml anti-HMGB1 antibody (rabbit IgG, Abcam, ab18256) for 1 h. Sections were then incubated with Alexa 488-conjugated F-actin phalloidin (1:500, Invitrogen, San Diego, CA, USA); Cy3-conjugated goat anti-rabbit IgG (1:1000, for anti-HMGB1 antibody, Jackson Immunoresearch, no.111165003) for 1 h. A Hoechst nuclear stain was applied for 30 s and slides were prepared for imaging. Imaging conditions were maintained at identical settings within each antibody-labeling experiment with original gating performed using the negative control. Large area images in X and Y using a Nikon A1 confocal microscope (purchased with 1S10OD019973-01 awarded to Dr. Simon C. Watkins).

**Mouse hepatocyte isolation and cell culture.** Primary mouse hepatocytes from WT and HC-HMGB1−/− mice were isolated and plated as previously described (21). Hepatocytes (150,000 cells/ml) were plated on gelatin-coated culture plates or coverslips precoated with Collagen I (Thermo Fisher Scientific, no.08774383) in Williams E medium with 10% calf serum, 15mM HEPES, 10−6M insulin, 2mM L-
glutamine, 100U/mL penicillin, and 100U/mL streptomycin. Palmitic acid (PA; Sigma-Aldrich, no. P0500)-induced fat accumulation in hepatocytes was established as previously described (13, 16, 22). PA was dissolved in 95% ethanol at 100mM stock solution, which was then mixed with Williams medium E containing 10% calf serum to 8mM stock concentration. PA concentration used ranged from 200 to 800μM, which is similar to fasting plasma total free fatty acid (FFA) concentration in human nonalcoholic steatohepatitis (23). Hepatocytes were allowed to attach to plates for 6h and cultured in serum-free media for 12h prior to the PA treatment. Isolated hepatocytes were exposed to tunicamycin (TM; Sigma-Aldrich, no. 654380) (2μg/mL for 6h) to induce ER stress, or pretreated with 4-phenylbutyric acid (PBA; Sigma-Aldrich, no. P21005) (200μM for 12h) to inhibit ER stress.

**Oxygen consumption rate (OCR) measurement.** WT and HC-HMGB1−/− mouse hepatocytes were plated in XF-96 cell culture plates (10⁴ cells/well; Agilent, no.101085) overnight. Hepatocytes were then washed and incubated for 1 h in XF assay medium (unbuffered DMEM pH 7.4) in a non-CO₂ incubator at 37 °C as per manufacturer's instructions (Agilent). Real time measurements of hepatocyte OCR were performed using an XF-96 Extracellular Flux Analyzer (Agilent). Three consecutive measurements were obtained under basal conditions and after the sequential addition of 4 μM oligomycin, to inhibit mitochondrial ATP synthase (complex V); 1 μM FCCP (fluoro-carbonyl cyanide phenylhydrazone), a protonophore that uncouples ATP synthesis from oxygen consumption by the electron-transport chain providing a maximal OCR value; and 1 μM rotenone which inhibits the electron transport chain providing a baseline/minimum value.

**Human hepatocytes isolation and culture.** Human hepatocytes were isolated from histologically normal liver and were kindly provided by Dr. David Geller (University of Pittsburgh Department of Surgery, Pittsburgh, PA) according to a protocol approved by the Institutional Review Board (24). Human hepatocytes were prepared by a three-step collagenase perfusion technique. Isolated human hepatocytes were cultured in William's medium E (Invitrogen, no.12551032) supplemented with 5% calf serum (GE Healthcare Life Sciences), penicillin (100 U/ml), streptomycin (100 U/ml), 2 mM L-glutamine, and 15 mM HEPES.

**LDH cytotoxicity Assay.** Culture medium from treated hepatocytes (50 μl) was transferred to a 96-well plate and the LDH reaction was performed using Pierce LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) following manufacturer's instructions. Absorbance at 680 nm (background signal) was subtracted from the absorbance at 490 nm. LDH activity was normalized to protein concentration and results are shown as fold of controls. At least three independent experiments with three replicates each were performed.

**Oil red O staining.** Hepatocytes from each experimental group plated in six-well plates were rinsed three times with PBS, fixed in 4% paraformaldehyde for 30min, stained for 60 min at RT in freshly diluted Oil Red O solution (0.5% Oil Red O in isopropanol: H₂O = 3:2), rinsed three times with PBS, redyed for 30sec in hematoxylin staining solution and rinsed with PBS twice. Intracellular lipid droplets were imaged with Nikon TS100 inverted microscope connected to a digital camera.
Real-time polymerase chain reaction (RT-PCR) analyses. Total RNA was extracted from liver tissue or hepatocytes using RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Total RNA (1 μg) was reverse transcribed using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, no. 1708891), according to the manufacturer’s instructions. The samples were then diluted, and the same amount of cDNA was added to each reaction on each plate. The iTaq universal SYBR Green supermix (Bio-Rad Laboratories, no. 1725121) and a different primer were used for gene expression analyses. All samples were run in triplicate, and the experiment was repeated three times. Primers used for carnitine-palmitoyltransferase 1α (CPT-1α), medium-chain acyl-CoA dehydrogenase (MCAD), long-chain acyl-CoA dehydrogenase (LCAD), very-long chain acyl-CoA dehydrogenase (VLCAD), fatty acid synthase (FAS), lipoprotein lipase (LPL), sterol regulatory element-binding protein 1 (SREBP-1), peroxisome proliferator-activated receptor gamma (PPAR-γ), adipophilin, collagen type 1A1 (COL1A1), collagen type 1A2 (COL1A2), tissue inhibitors of metalloproteinases (TIMP), α-smooth muscle actin (α-SMA), stearoyl-CoA desaturase-1 (SCD-1), and β-actin were ordered from Qiagen (Hilden, Germany). See Supplemental Table 2 for PCR primer sequences. Thermal cycling conditions were 10 min at 95 ° C, followed by 40 cycles of 95 ° C for 15 s and 60 ° C for 1 min on a sequence detection system (ABI PRISM 7000; Applied Biosystems). Each gene expression was normalized with β-actin mRNA content.

Immunoblotting. Western blot was performed using whole-cell lysates from either liver tissue or hepatocytes, as previously described (21). Total protein concentration of 1 μg /μl was loaded into the 12% gel for each specific western blot analysis. Membranes were incubated overnight with antibodies against Akt (Cell Signaling, no. 9272), phospho-Akt (p-Akt) (Ser473) (Cell Signaling, no. 9271), HMGB1 (Abcam, ab18256), β-actin (Abcam, ab8226), GAPDH (Abcam, ab8245), ATF6 (Abcam, ab37149) and CHOP (Abcam, ab11419). Secondary antibodies (no. 31460 and no. 31430) were from Thermo Fisher Scientific. For Western blot analyses, cell lysis buffer (1:10, Cell Signaling, no. 9803) was used for whole cell lysis and tissue lysis together with protease inhibitors. Western gel images were quantified by densitometry analyses using ImageJ software and presented as a ratio of loading controls.

Statistical analyses. Data are presented as mean ± standard error of mean (SEM). Experimental results are analyzed for their significance by Student’s t-test. Significance was established at the 95% confidence level (P <0.05).

Results

HFD triggers HMGB1 loss in hepatocytes and increases serum HMGB1 level

Extracellular HMGB1 has been identified as a mediator of HFD-induced liver damage and inflammation during the early stages of NAFLD (13). We examined HMGB1 expression, cellular location and release into circulation in HFD-fed mice. In WT mice as early as 2 weeks of HFD there was significant movement of HMGB1 into the cytoplasm and intercellular space of hepatocytes and this increased in a time-dependent manner. In contrast, HMGB1 remained in the nucleus of hepatocytes in the livers of LFD-treated WT mice (Figure 1A). Furthermore, serum HMGB1 levels increased 5 folds in HFD treated mice.
compared with LFD-treated mice after only 2 weeks of HFD, and this was maintained until 16 weeks (Figure 1B). Levels did not change over time in LFD treated WT mice. This confirms mobilization of HMGB1, and relative deficiency of HMGB1 in hepatocytes after HFD feeding. We also treated human and mouse hepatocytes with palmitic acid (PA), the most abundant fatty acid in HFD and in serum of NAFLD patients (25), and assessed HMGB1 levels. In both human and mouse cells HMGB1 levels decreased and HMGB1 levels in the culture medium increased with PA exposure, suggesting similar mobilization (Figure 1C-D). These results indicate that hepatocytes loss of HMGB1 and HC-HMGB1 is a major source of circulating HMGB1 during the development of NAFLD.

**HC-HMGB1 deficiency promotes early HFD-induced weight gain and obesity**

Since HMGB1 is closely linked to obesity and obesity-induced inflammation (26), we monitored the weight changes of WT and HC-HMGB1⁻/⁻ mice weekly. The body weight increase of mice was greater in the HFD group than in the LFD group over the 16-week experiment (Figure 2A). Interestingly, HC-HMGB1⁻/⁻ mice showed rapid, early weight gain, particularly over the first 4 weeks of HFD feeding, and gained significantly more body weight than WT mice by 8 weeks (Figure 2A). However, body weight of the HC-HMGB1⁻/⁻ mice was plateaued after 8 weeks, and was similar to that of the WT mice by 16 weeks. The weight gain of HFD-fed HC-HMGB1⁻/⁻ mice corresponded with increased body fat content (Figure 2B), suggesting altered lipid metabolism or storage.

**HC-HMGB1 deletion has no effects on glucose intolerance, food intake and energy expenditure**

Since obesity can lead to metabolic syndrome and hyperglycemia, we assessed glucose tolerance in both WT and HC-HMGB1⁻/⁻ mice. Glucose intolerance (Figure 2C) was increased after HFD in both WT and HC-HMGB1⁻/⁻ mice to a similar extent. The insulin signaling in hepatocytes from both genotypes was also analyzed by detecting phosphorylation of Akt, and we found that p-Akt was not affected by the knockout of HC-HMGB1 gene (Figure 2D-F). Dietary intake was also similar between WT and HC-HMGB1⁻/⁻ mice throughout 16 weeks of HFD or LFD administration (Supplemental Figure 1A). We also assessed energy expenditure in both strains and found no significant differences in \( V_{O_2} \) between WT and HC-HMGB1⁻/⁻ mice (Supplemental Figure 1B). These findings suggest that HC-HMGB1 may influence lipid metabolism in liver, and subsequent fat storage, without affecting systemic energy and glucose homeostasis.

**Increased hepatic steatosis and liver injury are observed in HC-HMGB1⁻/⁻ after HFD**

H&E-stained liver sections were next assessed for hepatic steatosis. HC-HMGB1⁻/⁻ mice developed severe steatosis as early as 2 weeks after HFD, and this was maintained for up to 16 weeks (Figure 3A). WT mice showed evidence of fat accumulation in liver after 16 weeks of HFD, but this was less extensive than in HC-HMGB1⁻/⁻ mice (Figure 3A). Interestingly HC-HMGB1⁻/⁻ mice on LFD also showed increased fat accumulation by 16 weeks (Figure 3A), which further suggests deficiencies in hepatocyte lipid metabolism and storage with HMGB1-deficiency. Hepatic steatosis score based on H&E-stained mouse
Liver sections is shown in Table 1. Consistently, hepatocytes lacking HMGB1 had increased lipid deposition at 24 h after PA treatment compared with controls, as shown by Oil O Red staining (Figure 3C). Despite obvious increased hepatic steatosis in HC-HMGB1−/− mice early, serum levels of ALT (marker of liver injury) and IL-6 (systemic inflammation) were not significantly higher compared to controls mice until 16 weeks (Supplemental Figure 2A-B). We also measured HMGB1 levels and found significantly lower levels of circulating HMGB1 in HC-HMGB1−/− mice compared with WT (Figure 3B), confirming the importance of liver and hepatocytes as sources of HMGB1 in the circulation. Given that circulating HMGB1 is a known inflammatory DAMP, it may be that the HC-HMGB1−/− mice are relatively protected from systemic inflammation despite increased hepatocyte stress and damage from lipid accumulation. Indeed, using an in vitro assay we showed that HC-HMGB1−/− hepatocytes were more susceptible to PA-induced cell death (Figure 3D). These results indicate that loss of HMGB1 increases liver injury and cytotoxicity in hepatocytes during NAFLD.

**Loss of HC-HMGB1 induces ER stress**

It is increasingly clear that perturbed ER proteostasis in hepatocytes is involved in pathogenesis of NAFLD through the activation of ER stress signaling (27), and pharmacological induction of ER stress increases hepatic steatosis during NAFLD (28, 29). We therefore assessed ER stress in livers of WT and HC-HMGB1−/− mice after LFD or HFD feeding. ER stress, indicated by levels of cleaved ATF6 and CHOP, was enhanced in HC-HMGB1−/− mice compared with WT regardless of HFD or LFD feeding (Figure 4A-C). Similarly, HMGB1−/− hepatocytes treated with PA in vitro had increased cleaved ATF6 and CHOP compared to similarly treated WT cells (Figure 4D). Consistently, the levels of cleaved ATF6 and CHOP was increased after PA treatment in human hepatocytes (Figure 4E). These results suggest a role for HMGB1 in homeostasis in hepatocytes via regulation of ER stress.

**Deletion of HC-HMGB1 down-regulates hepatic gene expression related to β-oxidation.**

Given our data above suggesting a role for intracellular HMGB1 in lipid metabolism in hepatocytes, we measured mRNA levels of mouse liver enzymes involved in FFA β-oxidation, lipogenesis and lipolysis. Dysregulation of these pathways contributes to lipid metabolic disorders and lipid accumulation (30-32). We screened multiple genes (Table 2), and found hepatic gene expression related to β-oxidation (CPT-1α, MCAD, LCAD and VLCAD) was significantly down-regulated in HC-HMGB1−/− mice compared with WT throughout the 8 weeks of HFD feeding (Table 2 and Figure 5A). To further investigate the underlying mechanisms we used our in vitro model of hepatocytes isolated from WT and HC-HMGB1−/− mice exposed to PA. Similar to our in vivo results, HMGB1−/− hepatocytes also had significantly decreased CPT-1α, LCAD and VLCAD gene expression after stimulation with PA (Figure 5B). Oxidative phosphorylation levels, and indication of metabolic activation of cells, were also lower in HC-HMGB1−/− hepatocytes compared with WT (Figure 5C). These data demonstrate that hepatocyte HMGB1 regulates lipid accumulation via β-oxidation-related gene expression, suggesting β-oxidation as a downstream target of intracellular HC-HMGB1 during NAFLD.
ER stress is associated with lipid accumulation in hepatocytes.

Having demonstrated that steatosis in hepatocytes lacking HMGB1 is accompanied by ER stress, we wanted to examine this relationship further. We therefore induced ER stress in WT mouse hepatocytes, using ER stress inducer TM (2 μg/mL for 6h). We confirmed induction of ER stress with TM (Figure 6A) and saw enhanced intracellular lipid accumulation in TM-treated cells after PA treatment (Figure 6C). Interestingly, we also saw suppression of the same b-oxidation genes (CPT-1α, MCAD, LCAD and VLCAD) in TM-treated WT hepatocytes suppressed in HMGB1-/- liver and hepatocytes (Figure 6D). We also inhibited ER stress in HMGB1-/- hepatocytes using 4-phenylbutyrate (200mM for 12h), and confirmed that this was able to reduce ER stress in response to PA treatment (Figure 6A-B). We saw corresponding reduced lipid deposition in cells (Fig.6C), and increased expression of key b-oxidation genes (Figure 6E).

Next we assessed b-oxidation gene expression in WT and HC- HMGB1-/- hepatocytes, as well as HC-HMGB1-/- hepatocytes transfected with plasmids expressing His-tagged HMGB1. Induced HMGB1 expression in HC-HMGB1-/- hepatocytes was able to significantly increase expression of CPT-1α and MCAD compared with control plasmid-treated cells (Figure 6F). However, the levels were still significantly lower than in WT cells. These data suggest that ER stress and HMGB1 are intricately linked with hepatocyte lipid metabolism.

Discussion

Understanding the mechanisms driving NAFLD and hepatosteatosis is key to developing new approaches to treatments. HMGB1 is a multifunctional protein that has specific biological functions dependent on its intracellular/extracellular location (7, 33). Extracellular HMGB1, released either passively after lytic cell death or actively from stressed and damaged cells, has been shown to be an important mediator of liver injury in NAFLD (13). It is also reported that HMGB1 mediates inflammatory pathway that is receptor for advanced glycation end products (RAGE) and redox signaling dependent and helps promote ectopic intestinal inflammation in NAFLD (34). This is consistent with the role of HMGB1 as a damage-associated molecular pattern contributing to injury, inflammation, apoptosis, and immune responses (2).

Circulating HMGB1 mainly comes from hepatocytes in multiple pathologies, including sepsis (35). Here we show that HC-HMGB1-/- mice have significantly reduced circulating HMGB1 in response to HFD feeding (Figure 3B), again confirming that hepatocytes are major sources of HMGB1. Recent studies suggest that HMGB1 is a key protein participating in the pathogenesis of acute liver injuries and chronic liver diseases (2, 12) with circulating HMGB1 levels correlating with severity of inflammation and fibrosis in NAFLD (14, 15). Increased circulating HMGB1 levels were confirmed in a mouse model of NAFLD, and neutralizing antibodies to HMGB1 were protective (17). Toll-like receptors (TLR)-2/4/9 and RAGE have all been shown to mediate HMGB1 signaling (2, 36). In 2011, Li et al. reported HMGB1 releasing from hepatocytes in response to FFA activates TLR4/MyD88 to induce cytokines expression in vitro and in vivo. Treatment with neutralizing antibody to HMGB1 protects against FFA-induced tumor necrosis factor alpha and interleukin-6 production (13). Chandrashekaran et al. also identified systemic circulating
HMGB1, acting via RAGE, as a key mediator accelerating intestinal inflammation in NAFLD (34). Despite that all these published data indicated extracellular HMGB1 may be detrimental in liver damage, there still exists controversy over the role of circulating HMGB1 plays in liver injury and its association with serum ALT. Although HMGB1 is found to be correlated with ALT activity during clinical acetaminophen hepatotoxicity (37), it is also reported that serum HMGB1 was not related to histological severity or serum ALT in adult and children NAFLD (38). In our mouse models, serum HMGB1 levels were significantly elevated by HFD from week 2, while ALT levels were not significantly different between HFD and LFD groups. To investigate the link among circulating HMGB1, serum ALT and liver damage, further studies to expand the results found here are warranted.

In sharp contrast to numerous studies examining the effect of extracellular HMGB1 on acute and chronic liver diseases, few studies have demonstrated the role of intracellular HMGB1 plays in liver damage, except that intracellular HMGB1 in hepatocytes has been shown to be protective during liver ischemia and reperfusion injury (18). So far, little is known about the role intracellular hepatocyte HMGB1 plays in the pathogenesis of NAFLD and liver cell injury. In this study, we uncover a novel pathway of hepatocyte HMGB1-mediated hepatoprotection from lipid accumulation, hepatosteatosis and liver damage during HFD feeding. Lack of HMGB1 increases ER stress in hepatocytes, and reduced b-oxidation resulting in increased lipid accumulation and cell injury.

ER plays an essential role in multiple cellular processes including secretory and transmembrane protein folding, calcium homeostasis and lipid biogenesis (39). Perturbation of ER homeostasis results in ER stress and activation of the unfolded protein response (UPR), which is initiated to restore ER proteostasis (40),(41). Emerging evidence points to an important role of HMGB1 in UPR and ER stress induced by Clostridium difficile Toxin A, one of the major virulence factors of C. difficile infection (42). Exogenous recombinant HMGB1 also induced ER stress in CT26 cells (the murine colon adenocarcinoma cell line), while glycyrrhizin, an HMGB1 inhibitor, decreased ER stress (42). Again, extracellular HMGB1 seems to induce detrimental signaling and increases liver cell injury and stress. However, our data in this study show that intracellular HMGB1 can actually be protective and plays a role in maintaining ER homeostasis and preventing FFA-induced liver damage.

Maintenance of hepatic ER homeostasis is pivotal for sustaining membrane lipid composition and maintaining both intrahepatic and plasma lipid homeostasis (32). The hallmark of NAFLD is the abnormal lipid accumulation in the liver, which subsequently leads to cellular stress and hepatic injury. Excessive hepatic fat accumulation often coincides with perturbed ER homeostasis in hepatocytes (29), and ER stress has been associated with NAFLD pathogenesis (27). ER membrane-localized transcription factors regulate de novo lipogenesis: sterol regulatory element-binding proteins (SREBP1c (SREBF1) for fatty acid synthesis and SREBP2 (SREBF2) for sterol synthesis (32). Hepatocytes also store lipids in the form of triglycerides that are synthesized from fatty acids and glycerol by ER-localized acyltransferase enzymes, including diacylglycerol acyltransferase (DGAT). Very-low-density lipoprotein (VLDL), which is assembled in the ER prior to trafficking to the Golgi (43), is an important mediator of lipid and cholesterol uptake into cells, including hepatocytes. Recently, Lebeaupin et al. reviewed available evidence linking ER
stress to NAFLD and concluded that chronic ER stress can affect hepatic lipid metabolism directly by inducing de novo lipogenesis, and indirectly through the alteration of VLDL secretion, insulin signaling and autophagy (29). Conversely, increased hepatocyte lipid content can also initiate chronic ER stress (29), creating a potential feed-forward potentiation of NAFLD-mediated liver damage. Our data suggest intracellular HMGB1 is integral to these homeostatic pathways and contributes to maintaining lipid homeostasis under normal and pathogenic conditions.

Given all those published data on the detrimental effects of extracellular HMGB1, we were initially surprised by our findings that HC-HMGB1 is protective in HFD feeding. However, our subsequent findings suggest that the intracellular effects of HMGB1-deficiency on cell stress and injury outweigh any benefit of reduced circulating HMGB1, highlighting the importance of effects on cellular lipid metabolism in the pathogenesis of NAFLD.

In addition, in this study we identified a remarkable increase of body weight gain, fat content and hepatic lipid accumulation in HC-HMGB1/−/− mice at as early as 2 weeks after HFD administration. Blood glucose, food intake and energy expenditure did not significantly differ between HC-HMGB1/−/− and WT mice over the same period. It seems that HC-HMGB1/−/− mice were more susceptible to obesity and fatty liver when HFD-fed than WT mice at the early stage. Intracellular HMGB1 may associate with the susceptibility of body weight increase and hepatic lipid deposition. By administering anti-HMGB1 antibody to C57Bl/6 mice, Montes et al.(44) previously reported that anti-HMGB1 treatment reduced weight gain in mice fed a high (60%)-fat diet from the second week and thus HMGB1 was inferred to play a crucial role in weight gain at the early stage of obesity, though they did not observe differences in glucose, insulin tolerance and adipose tissue inflammation between HMGB1 neutralizing and control groups. Taking all of these evidences together, despite that the mechanism of HMGB1-mediated weight change is incompletely understood, we could draw a preliminary conclusion that HMGB1 may have a key role in weight change at the early stage of HFD. More experiments should be undertaken to elucidate the crosstalk among intracellular HMGB1 in hepatocytes, body weight and fat content.

In our study, it is also interesting to see increases in steatosis and ER stress without increases in serum IL-6 (systemic inflammation) or ALT (liver damage). Our interpretation is that endogenous hepatic HMGB1 is having multiple effects, and our data suggest that hepatocyte-derived HMGB1 not only regulates lipid metabolism within cells, but also plays a role in promoting systemic inflammation and augmenting hepatocyte cell death as part of its role as a recognized DAMP. This is similar to effects we have seen in other model systems (e.g. sepsis) where hepatocyte-derived HMGB1 is the main source of HMGB1 and drives inflammatory responses and also can induce inflammatory cell death (35). In addition, for the minor differences seen between our in vivo and in vitro experiments, we accept that PA treatment in a more acute setting in vitro in isolated hepatocytes does not necessarily recapitulate the in vivo findings.

**Conclusions**
We demonstrate a novel protective role for intracellular hepatocyte HMGB1 in preventing HFD-mediated liver injury, in part through regulation of ER stress and fatty acid (FA) b-oxidation. Modulation of these pathways may therefore represent attractive future pharmacological targets to arrest NAFLD progression at an early stage. Whether the differences observed in HC-HMGB1/-/- and WT mouse strains are exclusively attributed to multiple differences in genetic background or whether the constitutive adaption of HMGB1/-/- hepatocytes plays a specific role in maintenance of liver ER homeostasis and lipid metabolism in this pathological state remains to be fully investigated. Further studies should be warranted to explore the possible HC-HMGB1-stabilizing therapeutic strategies for preventing the hepatic fat accumulation in early cases of NAFLD by way of regulating ER stress and FA b-oxidation.

**Abbreviations**

NAFLD: nonalcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis; HMGB1: High-mobility group box 1; DAMP, damage-associated molecular pattern; HC-HMGB1: hepatocyte-specific HMGB1; ER: endoplasmic reticulum; WT: wild-type; HFD: high-fat diet; LFD: low-fat diet; ALT: alanine aminotransferase; IL: interleukin; ELISA: enzyme-linked immunosorbent assay; H&E: hematoxylin and eosin; PA: palmitic acid; OCR: oxygen consumption rate; FCCP: fluoro-carbonyl cyanide phenylhydrazone; TM: tunicamycin; PBA: 4-phenylbutyric acid; CPT-1a: carnitine-palmitoyltransferase 1a; MCAD: medium-chain acyl-CoA dehydrogenase; LCAD: long-chain acyl-CoA dehydrogenase; VLCAD: very-long chain acyl-CoA dehydrogenase; FAS: fatty acid synthase; LPL: lipoprotein lipase; SREBP-1: sterol regulatory element-binding protein 1; PPAR-γ: peroxisome proliferator-activated receptor gamma; COL1A1: adipophilin, collagen type 1A1; COL1A2: collagen type 1A2; TIMP: tissue inhibitors of metalloproteinases; α-SMA: alpha smooth muscle actin; SCD-1: stearoyl-CoA desaturase-1; RT-PCR: reverse-transcriptase polymerase chain reaction; p-Akt: phospho-Akt; SEM: standard error of mean; FFA: free fatty acid; TLR: toll-like receptors; RAGE: receptor for advanced glycation end products; UPR: unfolded protein response; rHMGB1: recombinant HMGB1; SREBP: sterol regulatory element-binding protein; DGAT: diacylglycerol acyltransferase; VLDL: very-low-density lipoprotein; FA: fatty acid

**Declarations**

**Conflict of interest:** None to declare.

**Ethical Approval and Consent to participate** – All animal protocols were approved by IACUC

**Consent for publication** – all authors consent for publications – no patient participation in this study

**Availability of supporting data** – All supporting data including original/full length Western blots and original data are available upon request

**Competing interests** – the authors declare no competing interests
Funding – Work supported by grants from NIH: R01-GM102146 (MJS), R35-GM127027 (TRB), R01-DK102839 (ROD). ML was supported by the Natural Science Foundation of Hunan Province of China (2019JJ50844) and Central South University Education Reform Project (2020jy166-6).

Authors’ contributions: ML, JL, WL, CY and PL performed experiments; ML, MD, MJS and ROD designed experiments and hypothesis; MD, ROD and MJS reviewed and analyzed data; ML, MD, TRB, ROD and MJS wrote and edited the manuscript.

Acknowledgements: We thank Hong Liao and Danielle Reiser for technical assistance.

Authors’ information (optional): Minjie Lin former visiting research scholar in the Department of Surgery at the University of Pittsburgh from 8/1/2015 to 7/31/2017; Chenxuan Yang, former visiting research scholar; 10/24/2016 to 7/27/2018; Wenbo Li, former visiting research scholar 8/31/2016 to 8/31/2018; Junke Long, former visiting research scholar 6/30/2018 to 4/30/2020

References

1. Perumpail BJ, et al. (2017) Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. *World journal of gastroenterology* **23**: 8263-8276.

2. Chen R, et al. (2013) Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. *Molecular medicine (Cambridge, Mass.)* **19**: 357-366.

3. Calzadilla Bertot L, Adams LA. (2016) The Natural Course of Non-Alcoholic Fatty Liver Disease. *International journal of molecular sciences* **17**

4. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. (2008) HMGB1: Endogenous Danger Signaling. *Molecular Medicine* **14**: 476-484.

5. Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. *Nature genetics* **22**: 276-280.

6. K. AR, et al. Lack of Benefit on Brain Edema, Blood–Brain Barrier Permeability, or Cognitive Outcome in Global Inducible High Mobility Group Box 1 Knockout Mice Despite Tissue Sparing after Experimental Traumatic Brain Injury. *Journal of Neurotrauma* **0**: null.

7. Deng M, Scott MJ, Fan J, Billiar TR. (2019) Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation. *Journal of leukocyte biology* **106**: 161-169.

8. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. (2010) HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. *Autoimmunity reviews* **9**: 661-665.

9. Stros M. (2010) HMGB proteins: interactions with DNA and chromatin. *Biochimica et biophysica acta* **1799**: 101-113.

10. Stros M, Launholt D, Grasser KD. (2007) The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins. *Cellular and molecular life sciences : CMLS* **64**: 2590-2606.
11. Jingjing C, et al. (2015) The Role of HMGB1 in Cardiovascular Biology: Danger Signals. *Antioxidants & Redox Signaling* **23**: 1351-1369.

12. Gaskell H, Ge X, Nieto N. (2018) High-Mobility Group Box-1 and Liver Disease. *Hepatology communications* **2**: 1005-1020.

13. Li L, et al. (2011) Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. *Hepatology (Baltimore, Md.)* **54**: 1620-1630.

14. Alisi A, et al. (2014) Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. *Expert review of molecular diagnostics* **14**: 763-771.

15. Ganz M, et al. (2015) Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. *Journal of translational medicine* **13**: 193.

16. Zeng W, et al. (2015) Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. *Scientific reports* **5**: 16013.

17. Chen X, et al. (2018) Dual regulation of HMGB1 by combined JNK1/2-ATF2 axis with miR-200 family in nonalcoholic steatohepatitis in mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* **32**: 2722-2734.

18. Huang H, et al. (2014) Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in cellular protection. *Hepatology (Baltimore, Md.)* **59**: 1984-1997.

19. Chartoumpekis DV, et al. (2015) Notch intracellular domain overexpression in adipocytes confers lipodystrophy in mice. *Molecular metabolism* **4**: 543-550.

20. Ryu JE, et al. (2015) Evaluation of Nonalcoholic Fatty Liver Disease in C57BL/6J Mice by Using MRI and Histopathologic Analyses. *Comparative medicine* **65**: 409-415.

21. Scott MJ, Liu S, Shapiro RA, Vodovotz Y, Billiar TR. (2009) Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1 dependent mechanism. *Hepatology (Baltimore, Md.)* **49**: 1695-1708.

22. Malhi H, Bronk SF, Werneburg NW, Gores GJ. (2006) Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. *The Journal of biological chemistry* **281**: 12093-12101.

23. Takahara I, et al. (2017) Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice. *PloS one* **12**: e0170591.

24. Nussler AK, et al. (1995) Further characterization and comparison of inducible nitric oxide synthase in mouse, rat, and human hepatocytes. *Hepatology (Baltimore, Md.)* **21**: 1552-1560.

25. Gambino R, et al. (2016) Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. *International journal of molecular sciences* **17**: 479.
26. Zhang J, et al. (2017) HMGB1, an innate alarmin, plays a critical role in chronic inflammation of adipose tissue in obesity. *Molecular and cellular endocrinology* **454**: 103-111.

27. Pagliassotti MJ. (2012) Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease. *Annual Review of Nutrition* **32**: 17-33.

28. Rutkowski DT, et al. (2008) UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators. *Developmental Cell* **15**: 829-840.

29. Lebeaupin C, et al. (2018) Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. *Journal of Hepatology* **69**: 927-947.

30. Zechner R, et al. (2012) FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. *Cell metabolism* **15**: 279-291.

31. Bechmann LP, et al. (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. *Journal of hepatology* **56**: 952-964.

32. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. (2018) Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cellular and molecular life sciences : CMLS* **75**: 3313-3327.

33. Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. *Nature Reviews Rheumatology* **8**: 195.

34. Chandrashekaran V, et al. (2017) HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease. *Redox biology* **13**: 8-19.

35. Deng M, et al. (2018) The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. *Immunity* **49**: 740-753.e747.

36. Li LC, Gao J, Li J. (2014) Emerging role of HMGB1 in fibrotic diseases. *Journal of cellular and molecular medicine* **18**: 2331-2339.

37. Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. *Journal of Hepatology* **56**: 1070-1079.

38. Yates KP, et al. (2017) Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease. *PloS one* **12**: e0185813.

39. Hetz C. (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. *Nature Reviews Molecular Cell Biology* **13**: 89.

40. Lodish H, et al. (2008) *Molecular cell biology*. Macmillan.

41. Schröder M, Kaufman RJ. (2005) ER stress and the unfolded protein response. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* **569**: 29-63.

42. Liu J, Ma Y, Sun C-L, Li S, Wang J-F. (2016) High Mobility Group Box1 Protein Is Involved in Endoplasmic Reticulum Stress Induced by Clostridium difficile Toxin A. *BioMed research international* **2016**: 4130834-4130834.
43. Reyes-Soffer G, Ginsberg HN, Ramakrishnan R. (2017) The metabolism of lipoprotein (a): an ever-evolving story. *Journal of lipid research* **58**: 1756-1764.

44. Montes VN, *et al.* (2015) Anti-HMGB1 antibody reduces weight gain in mice fed a high-fat diet. *Nutrition & Diabetes* **5**: e161.

**Tables**

Table 1. Hepatic steatosis score based on H&E-stained mouse liver sections

| Group | Hepatic Steatosis Score |
|-------|-------------------------|
|       | LFD | HFD              |
|       | WT  | HC-HMGB1<sup>-/-</sup> | WT  | HC-HMGB1<sup>-/-</sup> |
| 2 w   | 0±0 | 0±0              | 0±0 | 2±0             |
| 8 w   | 0±0 | 1±0              | 1±0 | 3±0             |
| 16 w  | 0±0 | 1.75±0.50        | 3±0 | 3±0             |

* n=4 for each group; data presented as mean±SEM.

Table 2. Relative gene expression of hepatic CPT-1, MCAD, LCAD and VLCAD in WT and HC-HMGB1-KO mice on LFD or HFD for 8 weeks
| Gene       | mRNA Relative Expression |         |         |         |         |         |         |         |         |
|------------|--------------------------|---------|---------|---------|---------|---------|---------|---------|---------|
|            |                          | LFD     | HFD     |         | WT      | HC-HMGB1-/- | P value | WT      | HC-HMGB1-/- | P value |
| β-oxidation|                          |         |         |         |         |         |         |         |         |
| CPT-1α     |                          | 1.24±0.46| 0.63±0.24| 0.069   | 0.98±0.14| 0.56±0.18 | 0.010   |
| MCAD       |                          | 1.08±0.35| 0.57±0.15| 0.052   | 1.26±0.20| 0.48±0.07 | 0.002   |
| LCAD       |                          | 0.97±0.14| 0.91±0.07| 0.450   | 0.99±0.14| 0.52±0.14 | 0.003   |
| VLCAD      |                          | 1.01±0.34| 0.49±0.27| 0.054   | 0.91±0.021| 0.41±0.0  | < 0.001 |
| Lipogenesis|                          |         |         |         |         |         |         |         |         |
| FAS        |                          | 0.96±0.05| 0.87±0.32| 0.610   | 0.93±0.41| 0.78±0.18 | 0.550   |
| PPAR-γ     |                          | 0.96±0.04| 0.70±0.24| 0.120   | 1.87±0.66| 1.69±0.17 | 0.630   |
| SCD-1      |                          | 1.01±0.29| 1.47±0.39| 0.110   | 0.80±0.10| 2.32±0.98 | 0.053   |
| Adipophilin|                          | 0.89±0.21| 0.41±0.38| 0.091   | 2.78±1.99| 0.44±0.49 | 0.096   |
| Lipolysis  |                          |         |         |         |         |         |         |         |         |
| LPL        |                          | 1.18±0.25| 0.28±0.30| 0.004   | 0.16±0.15| 0.40±0.17 | 0.079   |
| SREBP1     |                          | 1.42±0.21| 1.16±0.21| 0.130   | 0.96±0.29| 0.62±0.14 | 0.098   |

* n=4 for each group; data presented as mean+/-SEM.

**Figures**
Figure 1

HMGB1 mobilization from hepatocytes of human and mice during HFD feeding. A: Representative confocal immunofluorescence imaging of liver tissue of WT mice after 2, 8 and 16 weeks of LFD or HFD feeding. HMGB1 (red), actin (green) and 4',6-diamidino-2-phenylindole (DAPI) nuclear staining (blue). Scale bars represent 20 μm. x60 magnification. B: Serum HMGB1 levels in WT mice after LFD or HFD feeding for 2, 8 and 16 weeks. N=8/gp; data represent mean±SEM; *P< 0.05 between indicated groups. C:
Representative Western blot images of HMGB1 in whole cell lysates of human (left) and WT mouse (right) hepatocytes at 24h after up to 800µM palmitic acid (PA) treatment. Images representative of at least 3 repeats. Ctrl=no treatment. GAPDH was used a loading control. D: HMGB1 levels in the culture medium of human hepatocytes with PA exposure. Data presented as mean±SEM. Data representative of at least three repeats. *P< 0.05 between indicated groups.

Figure 2

A

![Graph A](image)

B

![Graph B](image)

C

![Graph C](image)

D

![Graph D](image)

E

![Graph E](image)

F

![Graph F](image)
Body weight, fat content and glucose metabolism in WT and HC-HMGB1-/- mice up to 16 weeks after LFD or HFD feeding. A: Body weight measurements of WT and HC-HMGB1-/- (KO) mice. B: Fat content. C: Blood glucose tolerance test. *P< 0.05 between WT LFD and KO LFD, or WT HFD and KO HFD groups; NS, not significant. D-F: The insulin signaling. Western blot analyses of levels of Akt and p-Akt (insulin signaling markers) in WT and HC-HMGB1-/- (KO) liver at D: 2 weeks, E: 8 weeks and F: 16 weeks after LFD or HFD feeding. Lysates from one mouse liver per lane. Images representative of at least 3 repeated experiments.
Figure 3

Steatosis, liver injury, inflammation and serum HMGB1 levels in WT and HC-HMGB1-/- mice up to 16 weeks after LFD or HFD feeding. A: Representative H&E stained liver sections. n=4 for each group; ×40 magnification; scale bar, 50 μm. B: Levels of serum HMGB1 in mice subjected to LFD or HFD for 2 weeks, 8 weeks and 16 weeks. C: Lipid accumulation shown by Oil O Red Staining (red) in WT and HC-HMGB1-/- mouse primary hepatocytes at 24 h after PA (800 μM) treatment. D: Hepatocyte cytotoxicity (%) measured by LDH release in vitro after PA (800 μM) treatment for 24h. Data show mean±SEM for one experiment performed in triplicate and representative of three separate repeats. *P< 0.05 between indicated groups; NS, not significant.
Figure 4

ER stress in WT and HC-HMGB1-/- (KO) liver up to 16 weeks after LFD or HFD feeding, and in hepatocytes after PA treatment. Western blot analyses of levels of cleaved ATF6 and CHOP (ER stress markers) in WT and HC-HMGB1-/- (KO) liver at A: 2 weeks, B: 8 weeks and C: 16 weeks after LFD or HFD feeding. Lysates from one mouse liver per lane. D: Western blot of WT and HC-HMGB1-/- (KO) hepatocyte whole cell lysates in control (ctrl – no treatment), or time points up to 36 h after PA treatment. Gray analyses was
performed for quantization of protein expression. Three independent experiments were performed. All data are means±SEM. *P< 0.05. E: Western blot of human hepatocyte whole cell lysates in control (ctrl – no treatment), or 24 h after PA treatment. GAPDH and β-actin were used as a loading control. Images representative of at least 3 repeated experiments.

Figure 5

A

Liver CPT-1α  Liver MCAD  Liver LCAD  Liver VLDL

2 wk Relative Expression

HFD  LFD

WT  HC-HMG1-KO  WT  HC-HMG1-KO  WT  HC-HMG1-KO  WT  HC-HMG1-KO

8 wk Relative Expression

B

CPT-1α  MCAD  LCAD  VLCAD

Relative Expression

WT  HC-HMG1-KO  WT  HC-HMG1-KO  WT  HC-HMG1-KO  WT  HC-HMG1-KO

C

DMEM  Oligomycin  FCCP  Rotenone

ODR (pmol/min)

Time (min)

0  12  24  36  60  72  96  108  120

WT  HC-HMG1-KO

Figure 5
Deletion of HC-HMGB1 down-regulates hepatic gene expression related to β-oxidation in WT and HC-HMGB1-/- (KO) mice up to 16 weeks and mouse hepatocytes at 24 h after PA treatment. A: Relative gene expression of hepatic CPT-1, MCAD, LCAD and VLCAD in WT and HC-HMGB1-KO mice on LFD or HFD (n=4 for each group). B: Relative gene expression of CPT-1, MCAD, LCAD and VLCAD in mouse hepatocytes at 24 h after PA treatment (800 µM). C: OCR in WT and HC-HMGB1-/- mouse hepatocytes. OCR tracing includes vertical lines indicating time of addition of mitochondrial inhibitors: oligomycin (4 µM), FCCP (1 µM), and rotenone (1 µM). OCR was normalized to protein content and is shown as fold changes of normoxic control. Data are mean±SEM, graphs show collated data from 10 individual measurements from at least 3 separate experiments. *P< 0.05 between indicated groups; NS, not significant.

Figure 6

ER stress is associated with lipid accumulation in hepatocytes and suppression of β-oxidation gene expression. A: Western blots showing levels of ER stress markers (cleaved ATF and CHOP) in hepatocytes. WT mice with and without treatment with ER stress inducer tunicamycin (TM; 2 µg/mL) for 6 h. GAPDH was used as a loading control. Images representative of at least 3 repeated experiments. Gray analyses was performed for quantization of protein expression. Three independent experiments were performed. All data are means±SEM. *P< 0.05. B: Western blots showing levels of ER stress markers (cleaved ATF and CHOP) in hepatocytes from HC-HMGB1-KO mice with and without treatment with ER stress inhibitor 4-phenylbutyric acid (PBA; 200 µM) for 12 h. C: Lipid accumulation shown by Oil O Red Staining (red) in WT mouse hepatocytes treated with/without TM, or HC-HMGB1-KO mouse hepatocytes treated with/without PBA. x60magnification. Representative images of multiple fields of view. Experiment repeated at least twice. D: Relative gene expression of CPT-1α, MCAD, LCAD and VLCAD β-oxidation genes
in WT mouse hepatocytes treated with/without TM; E: Relative gene expression of CPT-1α, MCAD, LCAD and VLCAD β-oxidation genes in HC-HMGB1-KO mouse hepatocytes treated with/without PBA (n=4 for each group). Data are expressed as mean±SEM. *P< 0.05 between indicated groups. F: Representative Western blot image of HMGB1, Cpt-1α and MCAD protein expression in whole cell lysates of WT and HC-HMGB1-KO hepatocytes at 40 h after transfection with control plasmid (ctrl) or plasmid expressing HisHMGB1. Quantification of relative protein expression shown below. Data presented as mean±SEM. Data representative of at least three repeats. *P< 0.05 between indicated groups.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SuppFig1.TIF
- SuppFig2.TIF
- SupplementalTables.docx